The RNASEL Arg462Gln polymorphism was implicated in up to 13% of prostate cancer cases, with the resultant enzyme 3 times less active than the wildtype enzyme, and an association was found among Europeans and Africans between the RNASEL Arg462Gln polymorphism and sporadic prostate cancer risk[14]. Here, RNASEL is linked to Familial prostate cancer.